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Abstract
Introduction: Enuresis (or Nocturnal Enuresis) is defined as discreet episodes of urinary incontinence during
sleep in children over 5 years of age in the absence of congenital or acquired neurological disorders.
Recommendations:  Suggestions and recommendations are made on the various therapeutic options available
within a South African context. These therapeutic options include; behavioural modification, pharmaceutical
therapy [Desmospressin (DDAVP), Anticholinergic (ACh) Agents, Mirabegron (3-adrenoreceptor ago-
nists), and Tricyclic Antidepressants (TCA)], alternative treatments, complementary therapies, urotherapy,
alarm therapy, psychological therapy and biofeedback. The role of the Bladder Diary, additional investiga-
tions and Mobile Phone Applications (Apps) in enuresis is also explored. Standardised definitions are also
outlined within this document.
Conclusion:  An independent, unbiased, national evaluation and treatment guideline based on the patho-
physiological subcategory is proposed using an updated, evidence based approach. This Guideline has
received endorsement from the South African Urological Association, Enuresis Academy of South Africa
and further input from international experts within the field.
© 2018 Pan African Urological Surgeons Association. Production and hosting by Elsevier B.V. This is an open
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hese guidelines are based on national meetings (Phase 1) held
t the Department of Paediatric Urology, Rahima Moosa Mother
 Child (Coronation) Hospital, Johannesburg in November 2015,
nd (Phase 2), held at the Boston Scientific Centre of Excellence,
ryanston, Johannesburg in February 2016. These meetings were
eld to achieve local national consensus. To avoid any bias, this
uideline received added input and suggestions from 3 independent
nternational experts in the field of Paediatric Urology. Furthermore,
harmaceutical trade names are not written within this document.
harmaceutical companies and their representatives did not have
ny access to this document during any of the stages of its write-
p, format or publication. Contributing authors have not received
ny honoraria for their involvement in this guideline. An attempt is
m
e
a
[ BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ade to define, outline, caution, highlight and suggest an acceptable
reatment algorithm guideline for use in the management of chil-
ren suffering from Enuresis, within a South African setting. These
uidelines are aimed at general practitioners, paediatricians, urolo-
ists, paediatric nephrologists and hospital administrators, within
he private and public sectors of South Africa. We further aim
o update this guideline 3 yearly due to the rapid advancements
ithin this field of Medicine. Local barriers with implementing
his guideline include drug availability, costs, resources and med-
cal staff shortages. Recommended dosages are to be tailored to
atient habitus, weight, and renal function where necessary and
ust be cross referenced with an updated acceptable Medical Ref-
rence source where needed. This guideline has been structured
s a more comprehensive update to the previous local Guideline
1].
G
d
N
p
N
v
n
*
E
P
T
w
a
1
N
[
T
A
p
s
P
P
p
d
s
d
o
m
s
a
[
P
T
I
u
c
o
1
2
3The South African guidelines on Enuresis—2017 
This  guideline  has  been  endorsed  by  the:
South African Urology Association (SAUA), Enuresis Academy
of South Africa and members from the South African Paediatric
Nephrology Society.
Definitions  and  terminology  [2]
Definition*:
Enuresis (or Nocturnal Enuresis) is defined as discreet episodes of
urinary incontinence during sleep in children over 5 years of age in
the absence of congenital or acquired neurologic disorders.
Enuresis  can  be  divided  into  Mono-Symptomatic  Enuresis
(MSE)  or  Non-Mono-Symptomatic  Enuresis  (NMSE).
Monosymptomatic  Enuresis  (MSE):
Isolated Enuresis without other Lower Urinary Tract symptoms
(nocturia excluded), and without bladder dysfunction, is defined
as Monosymptomatic Enuresis.
Primary  Enuresis  (PMSE)
Children who have not had a dry period of at least 6 months.
Secondary  Enuresis  (SMSE)
Children who have had a previous dry period of >6 months.
Non-Monosymptomatic  Enuresis  (NMSE)
Children with enuresis and any other Lower Urinary Tract symp-
toms, such as daytime wetting or urgency are said to have
Non-Monosymptomatic Enuresis.
The  severity  of  enuresis  can be defined as
frequent  (>4 per week) or infrequent  (<4 per week).
Expected  Bladder  Capacity  (EBC)  can be defined by the following
published formulas [3–5]:
Koff’s formula for EBC [3]:
EBC (ml) = 30 ×  (age in years + 2)
Hjälmås’s formula, more  widely  used  formula  for EBC [4]:
EBC (ml) = 30 + (age in years ×  30)
Kaefer’s formula for EBC [5]:
if age less than 2 years old:
EBC = 2 ×  age (years) + 2 = capacity (ounces*)if age 2 years old or older:
EBC = age (years) [divided by] 2 + 6 = capacity (ounces*)
T
s
d3
*Conversion from ounces (oz): ml is roughly 1:30.
irls have been observed to have larger EBC than boys, BUT this
iscrepancy was not significantly significant [5].
octurnal  (night-time)  Polyuria  is defined as nocturnal urine out-
ut exceeding 130% of EBC for age [1].
octuria  is the complaint that the child has to wake at night to
oid. Unlike enuresis, nocturia does not result in incontinence, and
octuria is not necessarily indicative of a pathologic condition.
For  the  purpose  of  this  guideline:  Primary  Mono-Symptomatic
nuresis  (PMNE)  will  be  discussed,  unless  otherwise  specified.
revalence  &  associated  factors
he prevalence of enuresis episodes varies in children and decreases
ith age, with higher rates in the less developed countries [6,7]. In
 recent South African study, the overall prevalence of NE was
6.0%, with 14.4% of children suffering from mono-symptomatic
E (MNE) and 1.6% from NE with daytime urinary incontinence
8].
he male:female prevalence ratio of NE was 2:1 [8].
ssociations between NE, poor school performance and learning
roblems have been reported. In addition, NE may result in low
elf-esteem, leading to psychological problems [8].
arental  involvement  and  perceptions
arents often treat enuresis as a psychological problem. Therefore,
arental perception can often cause psychological damage to chil-
ren suffering from NE, through punishment, shaming and lack of
upport. Parental concern is often not high and as a result, most chil-
ren are not treated at all. The latter is partly because the condition
ften resolves spontaneously, or parents are unaware of treatment
odalities. Families tend to self-treat their children with behavioural
trategies such as fluid restriction, waking the child at night to void
nd counselling. These treatment strategies have a low success rate
8].
athophysiology
he  ‘three  systems  model’
n 2000 Butler and Holland, proposed a “three systems model” for
nderstanding PMSE [9]. The value of this model is that it helps
onceptualise therapeutic interventions. Enuresis is caused by one
r more of the following three “systems” (see Fig. 1):
) nocturnal polyuria associated with abnormal diurnal variations
of antidiuretic hormone (ADH)/arginine-vasopressin release
during sleep,
) detrusor overactivity/over active bladder [OAB],
) abnormal sleep/arousal patterns.he “three systems model” can also assist to outline a management
trategy for children who do not respond to standard treatment. Van-
er Walle et al. have suggested that a combination assessment of the
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Eig.  1  The “three systems” model—adapted from Butler et al. [9].
bove factor will identify subtypes of PMSE [below] and guide
reatment [11].
. Normal urine output at night and normal bladder capacity might
respond to either DDAVP or the alarm.
. Small bladder capacities for age are likely DDAVP-resistant and
might respond to the alarm.
. Children with nocturnal polyuria and normal bladder capacity
should respond to DDAVP.
. Children with nocturnal polyuria and reduced bladder capacity
may find combined therapy of alarm and DDAVP to be successful
[10,11].
or the purpose of simplicity within this guideline, we have
ummarised the 4 above subtypes into 3 [see algorithm
ig. 2—algorithm].
he  “bladder–brain  dialogue”  [12]
nother entity that has been observed in severe (refractory)* enure-
is is a phenomenon of long-term overstimulation from bladder
ignals, which suppress the functioning of the arousal center, thus
ffecting the brain arousability in affected children. Thus, overstim-
lation of this “bladder–brain dialogue” is postulated to result in a
ighter sleep, but difficulty with complete awakening, in children
ith severe (refractory)* enuresis.
According to their study, severe (refractory) enuresis was defined
s ≥5 wet nights per week [12].
ehavioural  modification
ehavioural  modification  includes:
General behavioural modification.Water intake.
Toilet behaviour.
T
oA. Adam et al.
eneral  behavioral  modification  [13]
ehavioural interventions/modifications propose that the nightly
dry state’ is a learned response which can be accomplished using
sychological conditioning methods.
ublished methods include:
Fluid  restriction
Fluid restriction limits nocturnal urine production, thus reducing
octurnal voiding demands. Day time restriction may worsen enure-
is episodes buy reducing the ‘Bladder Volume: Nocturnal Urine
roduction’ ratio.
‘Lifting’
Parents/caregivers ‘lift up’ the child while still asleep, and take
hem to the bathroom where urination is encouraged.
Scheduled  wakening
Involves scheduled wakening, with the sleep being interrupted
nd the child asked to void during the night.
Star  charts  and  other  reward  systems
This method uses a positive reinforcement method to promote a
hange in behaviour.
Bladder  training  and  retention  control  training
Attempts at increasing the bladder capacity is proposed by:
Increasing day-time fluid intake,
Delaying micturition [where possible],
Stream interruption exercises.
onclusion  and  comparative  assessment  review  of  the  overall
ffect  of  the  above
he above interventions were proven effective compared to no treat-
ent, BUT did not outperform active treatment methods [13].
ater  intake  in  children
ecommend as is appropriate, also see Scientific Opinion on Dietary
eference Values for water:
ttp://www.efsa.europa.eu/en/efsajournal/pub/1459.
oilet  behaviour
ncourage the child to always use the toilet before going to bed
asy access, adequate lighting, to the bathroom must be in placeoilet  position
If seat too big the child ‘falls in’, thus can be obstructing urethral
utlet,
The South African guidelines on Enuresis—2017 5
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Lean forward with elbows resting on thighs,
Feet should be resting on a foot stool/platform/ground,
Encourage overall hygiene.
Pharmaceutical  therapy
Desmospressin  (DDAVP)
DDAVP is the synthetic equivalent of the posterior pituitary hor-
mone, vasopressin (AntiDiuretic Hormone (ADH)).
Monotreatment in cases of Nocturnal  Polyuria  has been recom-
mended.
DDAVP is preferred for camps and sleepovers. A trial to test the
response is suggested 6 week prior.
Although hyponatreamia is uncommon, fluid intake
should  be  avoided  an hour before and 8 h after taking the
medication.
Duration of action may be prolonged if administered in a fasting
state [14].
Contraindications:  Hyponatraemia, renal failure, known hypersen-
sitivity [15].
p
cis [Management Algorithm—portrait view].
ormulations  available
ral  tablet:
Initial dose: 0.2 mg (Max 0.4 mg) daily.
Only consider dose escalation after 2 weeks of initial treatment.
aution with escalation; prolonged bioactivity is suspected if chil-
ren do not have a morning void. If this is the case, the dose should
ot be increased.
DAVP  nasal  spray
Caution:  Over-dosage reports resulting in seizures and hypona-
raemia with Nasal Spray administration have limited the use of this
oute in the management of enuresis—FDA ALERT [12/4/2007].
ELT  [oral  desmopressin  lyophilisate]
Suggested/recommended MELT dosage (120 mcg, 240 mcg)
aily.
Children showed a preference to MELT formulation in a ran-
omised study of MELT vs tablet formulation [16].Although structured withdrawal programs did not show benefit
reviously [17], newer meta-analysis reported on better overall out-
omes with a dose-dependent structured withdrawal regimen [18].
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MELT [Oral Desmopressin lyophilisate] formulation has recently
een made available in South Africa.
n conclusion, DDAVP can be used as monotreatment or in combi-
ation with alarm therapy [19].
nticholinergic  (ACh)  agents
fficacy,  sub  types,  recommended  dosages
igh-quality evidence for/against anticholinergic medication as
ole/combination therapy in PMNE is lacking [20]. Small functional
ladder capacity associated with Nocturnal Enuresis is an indication
o consider anticholinergics.
ypes  of  anti-cholinergics:
xybutynin is widely used, but fesoterodine, tolteridine, solifenacin
re also effectively used in treating the bladder overactivity com-
onent in children [21]. Oxybutynin has more side effects, but the
ewer anticholinergic agents are not yet registered for the use in
hildren in South Africa, but are being used effectively nonetheless
22,23].
ecommended/suggested  dosage:
xybutynin: children over 5 years; 5 mg up to 3 times daily.
otential off label use:
olterodine: 0.12 mg/kg daily dose [24].
olifenacin: 0.1–0.2 mg/kg daily dose. Solifenacin is currently used
ff label in South Africa, but is available as a 5 mg, 10 mg tablet [25].
he Anticholinergic ‘Patches’ are not yet available in South Africa,
t the time of writing.
ontraindications:  Myasthenia Gravis, glaucoma, hypertension,
owns syndrome, known hypersensitivity.
omplications,  compliance
n adults, anti-cholinergics are well documented regarding efficacy
nd tolerability. In children, however, evidence-based studies are
imited and vary across these compounds. This is demonstrated by
ifferent levels of evidence and grades of recommendation for oxy-
utynin (Grade 3C), propiverine (Grade 1B/C), tolterodine (Grade
C), and trospium chloride (Grade 3C) awarded by the International
onsultation on Incontinence [26].
tudies show that adverse effects were less frequent in children
han in adults [21]. Common side effects include dry mouth and
yes, constipation, facial flushing, drowsiness and cognitive effects
27].
irabegron  (3-adrenoreceptor  agonist)
irabegron, is a 3-adrenoreceptor agonist used in the management
f Over Active Bladder [OAB] [28].
 recent ‘pilot’ study has been performed in children with isolated
AB intolerant/refractory to ACh therapy. Daytime continence
h
iA. Adam et al.
mproved in 52 of 58 patients recruited. Only 8 patients reported
n mild to moderate side effects from therapy [28].
he precise role of Mirabegron (3-adrenoreceptor agonist) in
he management of Enuresis with an OAB component, may seem
romising. But since this therapeutic option has not yet been
xplored, this agent cannot be recommended as routine therapy
ithin this current guideline.
mipramine—Tricyclic  Anti-Depressant  [TCA]
mipramine is a Tricyclic Antidepressant associated with a 50%
esponse rate and is thought to act through brainstem central sympa-
homimetic/noradrenergic action promoting arousal and inhibiting
icturition [29]. Imipramine also increases the nocturnal anti-
iuretic hormone (ADH) excretion restoring the morning plasma
evels of ADH [30]. It is recommended that imipramine only be used
n therapy resistant older children with attention deficit hyperactiv-
ty who are severely distressed by their condition, when primary and
econd line treatments (the alarm, desmopressin, basic urotherapy
nd anti-cholinergics) have failed. In the case of a child with a family
istory of unexplained cardiac death, or who complains of syncope
nd heart palpitations, prolonged QT syndrome must be excluded
ith electrocardiogram recording [31]. Psychological side effects
ike mood changes may be bothersome during the first weeks of
herapy but usually recedes without dosage change. Drug holidays
re important to prevent tolerance and one strategy is to stop ther-
py after every 3 months for at least 2 weeks. Imipramine therapy
ay be combined with the bed alarm or desmopressin. However,
mipramine combined with alarm therapy did not show superior
ffectiveness compared with alarm therapy in isolation [32,33].
osage  utilised:  25 mg–50 mg daily one hour before bedtime [34].
aution:  TCAs are highly metabolised by Cytochrome (Cyt) P450
o concurrent use of drugs that inhibit Cyt P450, may cause TCA
oxicity. Also beware of other concurrent medication usage which
ay also cause QT prolongation.
ecommendations when TCA is used as therapy for enuresis:
. The child has no response to all other treatments.
. When a team with expertise in bedwetting evaluated the child
and determined that the alarm and/or desmopressin therapy has
failed.
. Parents must be informed on how imipramine works and that not
all children will experience improvement.
. The parents must know that the dose must be increased gradually
and when the therapy is discontinued also withdrawn gradually.
. Cardio-toxicity is a potentially lethal condition associated with
over dosage in children.
. The initial course is three months, and there is a high relapse rate
when therapy is stopped. Restarting to be decided on a case by
case basis.
. Imipramine must be stored and locked in a safe place out of the
reach of other children.. Baseline pre-treatment evaluation must include: History (includ-
ing family history), BP, Pulse and Resting ECG [34].
. Various published opinions, expressing the pros  and  cons  of
Imipramine usage from South African and international expert
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editorial correspondence needs to be considered when reviewing
cost issues while counselling parents/care givers [35,36].
j. Evidence does support a positive response during active treatment
phase with TCAs, but relapse rates are significant on cessation.
Combination therapy with anti-cholinergics have been observed
to outperform tricyclic usage in isolation [20].
. Combination (Imipramine & Oxybutynin) treatment was shown
to be more effective than imipramine used in isolation (RR 0.68,
95% CI 0.50–0.94) [37].
l. Imipramine has a low therapeutic to toxin drug ratio. Fatalities
have occurred in children at doses as low as 15 mg/kg [38].
Alternative  treatment/complementary  therapies
This includes the use of medicinal herbs, hypnosis, acupuncture,
chiropractic therapy and psychotherapy. Some weak evidence to
support the use in enuresis does exist, but the methodological
approach used in most of these studies are non-scientific. To docu-
ment the role of these agents in enuresis, future randomized trials
are needed [39,40].
Urotherapy
Urotherapy refers to the conservative and behavioural adjustments
that patients and parents can make and encompasses management
from a wide field of healthcare professionals [2].
The aim is to improve the bladder control in 3 domains:
1. Increase bladder capacity,
2. Decrease night time urine output,
3. Sensitize unconscious awareness of bladder filling.
Techniques include; daily increase in fluid intake, reduced nightly
intake, regular bladder emptying, pre-bedtime voiding, daily bowel
action, functional awareness training, avoid caffeine and high sugar
containing drinks [19,41].
Urotherapy encompasses the following standard components [2]:
(1) Information/demystification.
(2) Instruction.
(3) Life-style advice.
(4) Registration of symptoms and voiding habits (Diary/Apps).
(5) Support (encouragement) with the caregiver.
Significant improvement occurred in more than 70% of cases when
Urotherapy was used as initial therapy [41].
Alarm  therapy
Alarm therapy is based on a device that gives a strong sensory signal
(mostly acoustic), immediately after an incontinence episode [2].
The ‘Bed Wetting Alarm’ is also known as the Bell and pad method
or Bell and pad alarm therapy.A sensor pad is placed within the underpants or on the bed sheet. This
sensor is activated before reclining to sleep. Alarm triggering occurs
during contact with ‘wet’ urine. The alarm is sounded, causing a
C7
udden cessation in micturition. The child is then encouraged by
he parent/care giver to wake up and complete the void.
he alarm should initially be worn every night, with treatment with-
rawal evaluation at 12 weeks or if dry for 2 consecutive weeks.
nitiation of this therapeutic method requires a motivated family and
nvironment who understand the potential disruptive nature of this
reatment modality.
he child should be encouraged to manage the alarm and be part of
he process. Combination and Isolation therapy can be considered.
arious types of alarms are available: Pad-type alarms/Wired
larms/Wireless alarms.
xcessive sweating may falsely trigger the alarm. Poor contact,
aulty device or ‘flat’ batteries may cause device malfunction.
nline purchase from certain agencies within South Africa, costs
pproximately ZAR 300–ZAR 3000. Costs of the linen savers, bat-
eries, laundry are also needed to be factored in, when counselling
arents.
his modality should be combined with rewards and motivational
ncouragement.
ealistic published expected outcomes, observed initial response
ates up to 84% and relapse rates of 30%. Furthermore, better out-
omes are associated with patient willingness and female gender
42].
Overlearning” (having a large drink before bed while continuing
larm training) in a child who has learnt to be dry by sleeping through
he night may further reinforce waking to void if needed, and thus
educes relapse. If relapse occurs, repeating alarm training may also
ssist [43].
 recent Cochrane review further observed that alarm therapy was
ound to be superior to oxybutynin therapy (RR 3.25, 95% CI
.77–5.98) [37].
larms using electric shocks were unacceptable to children or their
arents and are no longer available.
larms may ‘beeb’, vibrate or play a recorded voice. However,
here is insufficient evidence available to draw conclusions about the
omparitive effectiveness of the different available alarm types [44].
sychological  issues
sychological  issues  have been an accepted role player/co-existing
actor in the pathogenesis of enuresis [45].
sychological  subclinical  symptoms  include:
uilt, sadness, humiliation, moodiness and embarrassment.linical  conditions  associated  with  enuresis  include:
Externalizing disorders [Conduct Disorder, ADHD].
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Internalising disorders [Anxiety, Depression].
Mixed disorders [Anorexia, Autism Spectrum].
sychological  screening
ince clinicians may have limited consultation time during busy
ut-patient clinics, the following validated published psychological
creening modalities can be performed in the waiting rooms:
 Short Screening Instrument for Psychological Problems in Enure-
sis (SSIPPE) [46].
 Child Behaviour Checklist (CBCL) [47].
arly  referral
f an underlying psychological disorder is suspected, early refer-
al for formal psychological assessment and management may be
arranted as part of the multi-disciplinary approach to enuresis.
he high risk groups for a negative Impact on Quality of Life are:
lder age and female gender [48]. If confirmed by SSIPPE, these
atients may merit fast tracked psychological treatment/referral.
iofeedback
iofeedback is a specific intervention of urotherapy that involves
elvic floor muscle retraining [2]. Biofeedback has been proven
ffective in the treatment of children with a functionally small blad-
er capacity. This method also allows children to hold larger (normal
or age) volumes for longer periods, without any leaking episodes
49,50].
obile  Phone  Applications  (Apps)  in  enuresis
he South African Smartphone market growth is amongst the high-
st in the world, with a yearly increase in growth of above 10%
orecasted on each year, up to and including the year 2018 [51]. The
lectronic ‘Bladder Diary’ was observed to be less cumbersome and
ore user friendly and thus showed superiority over the traditional
Pen and Paper’ bladder diary [52].
hese above factors make the use of Apps in the management of
nuresis a vital resource, especially since various Apps are custom
esigned for the management of this condition. Apps with Blad-
er Diary and management features are available on both the iOS
Apple) and Google Play Store (Android) platforms [53].
 recent independent review, ranked, evaluated and assessed all
vailable Apps in the management of Enuresis. The top three per-
orming Apps were ranked as: ‘My  Dryness  Tracker’, ‘Bedwetting
racker’, and ‘HapPee  Time’ [53].
eferring doctors, therapists, patients and their families should be
ncouraged to embrace this technological adjunct in the evaluation,
reatment and follow-up of enuresis.reatment  outline  &  algorithm
 suggested treatment algorithm is proposed. Please  see  Fig. 2
Management  Algorithm—Portrait  View]
R
sA. Adam et al.
BD  (Bladder  Bowel  Dysfunction)  and  constipation
ladder  and  Bowel  Dysfunction  (BBD)
BD denotes the presence of concomitant, parallel, bladder and
owel disturbances. BBD has thus replaced the term Dysfunctional
limination Syndrome (DES), and is now referred to as the umbrella
erm encompassing both components of Lower Urinary Tract (LUT)
ysfunction and bowel dysfunction [2].
onstipation
ontroversy exists in the pinpoint diagnosis of Functional  Consti-
ation  (FC),  however the international accepted practice largely
dheres to the Rome III (now updated Rome IV) criteria [54],
or a diagnosis of this condition [2]. The association between FC
nd LUTS, including enuresis, is well established [2,55]. Thus,
he screening of both components, are necessary to exclude BBD
2]. The presence of FC has even shown to be more preva-
ent in cases of ‘Pad Alarm failure’ in children with enuresis
56].
onstipation is frequently missed by parents and physicians alike,
nd a specific history and examination is necessary to elicit this
ondition [56].
arents and children should be asked about the frequency of defae-
ation, the presence of large or painful stools, straining, soiling or
eakage of faecal content into the underwear, and retentive behaviour
actively withholding defaecation out of fear for pain). Retentive
ehaviour may also be a result of a sibling birth, bereavement,
chool issues, or occult sexual abuse which may be missed dur-
ng a rushed, scanty history-taking session. During the examination
pecific attention should be paid to the presence of faecal masses in
he suprapubic or left lower quadrants of the abdomen, signifying
igmoid impaction [55].
tool consistency can be assessed using the Bristol  Stool  Chart  or
 Bowel Dairy for a period of 7 days.
links below]:
ttp://www.sthk.nhs.uk/library/documents/stoolchart.pdf
r
ttp://static1.1.sqspcdn.com/static/f/1451532/22180508/
363249562587/bristol stool chart.pdf
r
ttp://www.evelinalondon.nhs.uk/resources/patient-information/
ladder-bowel-diary.pdf
ommencement of treatment towards the FC should be the initial
ourse of action, as treatment for the associated enuresis may not
e needed, if FC is present and adequately dealt with [55].ecommended treatment options for FC within a South African
etting, includes:
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Treatment consists of disimpaction with oral and/or rectal laxatives.
Oral polyethylene glycol is currently the preferred treatment, at a
suggested dose of 1,5 g/kg/day for disimpaction and 0.8 g/kg/day
for maintenance.
Behavioural modification and fluid maintenance with treatment,
should aim to keep stools soft [55]. The management of FC in enure-
sis, is thus listed on the top bar within our proposed Algorithm, (see
Treatment Algorithm  Fig. 2), as the management of FC may result
in resolution or better symptom control and management of enuresis
in children with co-existing FC.
In the severe, refractory cases of FC, referral to a paediatric gastro-
enterologist, may be necessary, with plans towards a more thorough
evaluation process, which may include: defecography, colon transit
measurement and anorectal/colonmanometry [55].
The  bladder  diary
A bladder diary is also called a frequency: volume chart. In its most
basic form it is used to track the number of voids as well as the
volume of urine voided. This information is ideally collected over
a period of two days, which do not need to be consecutive. A 3 day
diary is recommended, however, patient compliance is improved
with a 2-day diary compared to a 3-day diary [2,57,58].
Polyuria and constipation may need an extended duration (7 day)
Bladder Diary days if suspected, as these issues may only arise on
days 4–7 of the assessment period. The night-time voided volume is
calculated by adding the first morning voided volume to the increase
in the night nappy weight.
The aim of the bladder diary is to objectively record and document
bladder function. A complete bladder diary consists of a 7-night
recording of incontinence episodes with nocturnal urine volume
measurements, accompanied by a 48 h daytime frequency/volume
chart (not necessarily two consecutive days). The frequency volume
chart is used to assess for the absence/presence of Lower Urinary
Tract dysfunction [2,57,58].
Clues to the ‘3 Systems model’ (pathophysiological sub-type) can be
explored during the assessment of the bladder diary (see Treatment
Algorithm  Fig. 2).
As a guide, the following Bladder Diaries are suggested (links to
the PDF Document):
http://www.monashchildrenshospital.org/wp-content/uploads/
2016/10/15050 Bladder diary form.pdf
or
https://www.aci.health.nsw.gov.au/ data/assets/pdf file/0004/
155911/enable bladder diary.pdfor
http://www.evelinalondon.nhs.uk/resources/patient-information/
bladder-bowel-diary.pdf.
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nuresis  and  Attention  Deficit  Hyperactivity  Disorder
ADHD)
DHD does not cause enuresis and enuresis is not listed as a symp-
om of ADHD. However, several studies indicate an association
etween these two diagnoses, with a higher incidence rate of enure-
is in children with ADHD and an increased prevalence of ADHD
n children with enuresis [59,60].
nuresis and ADHD are both complex problems resulting in a lot
f anguish for the child and the parents/caregivers. Both conditions
eed to be approached with care and compassion. Parents/caregivers
hould seek assistance and persist with treatment of both conditions
or optimal results.
nuresis  and  Adeno-Tonsillar  Hypertrophy  (ATH)
he concept of upper airway obstruction leading to sleep disordered
reathing has been well documented in the literature, and ATH has
een listed as one of the commonest underlying causes of sleep
isordered breathing, in this age group [61]. Various studies have
ocumented an increased prevalence of enuresis in children with
TH [62–64].
athophysiology  of  this  association
he pathophysiology of this association may be explained by a few
ostulated theories, which include; a sup-optimal arousal response,
ue to sleep fragmentation resulting from disordered breathing dur-
ng sleep. The presence of an obstructive airway compensates with
n increased respiratory effort, which may cause elevated intra-
bdominal pressure which may be transmitted to the bladder. Lastly,
leep disordered breathing, in general, may also result in an elevated
trial Natriuretic Peptide (ANP) and a decreased ADH [65,66].
hese above factors may explain why the association of ATH and
nuresis, is a more commonly reported entity.
ssessment  and  management  impact
ith regard to the assessment and management of the child with
TH, early well designed studies may have proven that the benefit
f adenotonsillectomy in children with enuresis, was not significant
o result in an improvement of enuresis symptoms [67].
owever, the benefit of adeno-tonsillectomy is now more supported
ith later studies showing vast ranges of improvement in enuresis
ontrol post-adenotonsillectomy [62,64,68–73].
hus, the general examination should include the assessment of the
onsillar crypts for ATH, with referral to our otorhinolaryngology
olleagues where necessary.
dditional  investigations
rior to additional investigations, clinicians should consider the
easons for poor treatment response, which includes:
ncorrect alarm use, sleep apnea, occult constipation, social, psy-
hological and emotional factors.
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he majority of children do not need further investigations, however
mongst the refractory category, and poor responders, triggers for
urther investigations are decided on an individual case bases [74].
nvestigations to consider in this category include:
 bladder ultrasound [Including capacity, bladder wall thickness
and post-void residual volume],
 renal ultrasound,
 urine flow rate,
 filling and emptying cystometrogram (Urodynamics Study).
 anorectal manometry.
efinitions  of  treatment  outcome  [2]
n the clinical setting, the child and family/care givers should be
llowed to define their appropriate benchmarks for treatment suc-
ess.
n the Academic setting and to maintain a better specialist refer-
al/research platform, a uniform standard of definitions have been
roposed:
nitial  success:
No-response: <50% reduction.
Partial response: 50–99% reduction.
Complete response: 100% reduction.
ontinued  success:
No relapse within 6 months after interruption of treatment.
elapse:
More than one symptom recurrence, per month.
omplete  success:
No relapse in two years after interruption of treatment
onclusion
ith an overall incidence above 14%, Enuresis has a major impact
n the children of South Africa [8]. An independent, unbiased,
ational evaluation and treatment guideline, expanding on the pre-
ious summarised guideline [1], is proposed.
ecommended/useful  links
ttp://i-c-c-s.org/
ttp://bedwetting.elsevierresource.com/
ttp://www.stopbedwetting.org/hcp/resourcesttp://www.espu.org/
ttp://www.bapu.org.uk/
S
A
tA. Adam et al.
ttp://www.eric.org.uk/
ttp://www.bedwetting.ie
ttp://www.continence.org.au/pages/bedwetting.html
ttp://www.rch.org.au
ttp://www.gosh.nhs.uk
ttp://www.uptodate.com/contents/nocturnal-enuresis-in-
hildren-management
ttps://www.bladderandbowelfoundation.org/bladder/bladder-
onditions-and-symptoms/nocturnal-enuresis/
ttps://www.healthychildren.org/English/health-issues/
onditions/genitourinary-tract/Pages/Nocturnal-Enuresis-in-
eens.aspx
ttp://svenskaenures.se/?language=en
ttp://www.spuonline.org/
ttp://www.drydawn.com
ttps://www.worldbedwettingday.com/
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